8-K: Instil Bio Leases Tarzana Facility to AstraZeneca for 15 Years

Instil Bio's subsidiary, Complex Therapeutics LLC, has entered into a 15-year lease agreement with AstraZeneca Pharmaceuticals LP for its Tarzana, CA facility.

Summary

• Instil Bio's subsidiary, Complex Therapeutics LLC, has leased its Tarzana, CA facility to AstraZeneca Pharmaceuticals LP.
• The lease agreement has an initial term of 15 years, commencing on July 10, 2024, and ending on July 31, 2039.
• AstraZeneca has two options to extend the lease for five years each and a one-time option to terminate on the tenth anniversary with a termination fee.
• The initial base rent is $627,276 per month, totaling $7,527,312 annually, with a 3% annual escalation.
• AstraZeneca will also cover operating and tax expenses as additional rent.
• There is a rent abatement period during the first year, meaning AstraZeneca will pay no or reduced rent.
• AstraZeneca has a right of first offer to purchase the leased premises.

Sentiment

Score: 8

Explanation: The lease agreement is a positive development for Instil Bio, providing a stable, long-term revenue stream with a reputable tenant. The terms are favorable, and the risks are relatively low.

Positives

• The 15-year lease provides a long-term, stable revenue stream for Instil Bio.
• The annual rent escalation of 3% ensures increasing revenue over the lease term.
• AstraZeneca, a major pharmaceutical company, is a reliable tenant.
• The lease includes options for AstraZeneca to extend, potentially increasing the lease term and revenue.
• The right of first offer to purchase the premises could lead to a future sale of the property.

Negatives

• The rent abatement during the first year will result in reduced or no rental income for that period.
• The one-time termination option after 10 years introduces some uncertainty to the long-term revenue stream.

Risks

• AstraZeneca could choose to terminate the lease after 10 years, impacting long-term revenue.
• The lease agreement is subject to the full terms and conditions of the lease document, which is not fully detailed in this report.
• The lease is dependent on AstraZeneca's continued operations and financial stability.

Future Outlook

The lease agreement provides a stable, long-term revenue stream for Instil Bio, with potential for increased revenue through annual escalations and lease extension options. The right of first offer to purchase the premises could lead to a future sale.

Management Comments

• The report was signed by Sandeep Laumas, M.D., Chief Financial Officer and Chief Business Officer of Instil Bio, Inc.

Industry Context

This lease agreement is a positive development for Instil Bio, as it monetizes a real estate asset and secures a long-term tenant in the pharmaceutical industry. It is common for biotech companies to lease out facilities to generate revenue.

Comparison to Industry Standards

• Leasing commercial real estate is a common practice for biotech companies to generate revenue from non-core assets.
• A 15-year lease term is relatively long, providing stability compared to shorter-term leases.
• The 3% annual rent escalation is a standard feature in commercial leases, reflecting inflation and market conditions.
• AstraZeneca is a large, established pharmaceutical company, making this a low-risk tenant compared to smaller or less established companies.
• Comparable lease agreements in the biotech sector often include similar terms, such as extension options and termination clauses.

Stakeholder Impact

• Shareholders will benefit from the long-term revenue stream and potential for future asset sales.
• Employees may see increased job security due to the company's improved financial position.
• The lease agreement does not directly impact customers or suppliers.

Next Steps

• Instil Bio will file the full lease agreement as an exhibit to their Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024.

Key Dates

Keywords

lease agreement, AstraZeneca, real estate, commercial lease, rental income, Tarzana facility, Instil Bio, Complex Therapeutics